ALIAS (Albumin in Acute Ischemic Stroke) Trials: Analysis of the Combined Data From Parts 1 and 2 [Clinical Sciences]
Conclusions—
Treatment with intravenous albumin 25% at 2 g/kg was not associated with improved outcome at 90 days and was associated with increased rates of intracerebral hemorrhage and pulmonary edema.
Clinical Trial Registration—
URL: https://www.clinicaltrials.gov. Unique identifier: NCT00235495.
Source: Stroke - Category: Neurology Authors: Martin, R. H., Yeatts, S. D., Hill, M. D., Moy, C. S., Ginsberg, M. D., Palesch, Y. Y., for the ALIAS Parts 1 and 2 and NETT Investigators Tags: Clinical Studies, Ischemic Stroke Clinical Sciences Source Type: research
More News: Clinical Trials | Health | Hemorrhagic Stroke | Ischemic Stroke | Neurology | Statistics | Stroke | Study